AngelMD's venture capital fund invested in a bone biologic startup.
Here are six takeaways:
1. The startup, Artoss, seeks to enhance bone grafting technology via nanotechnology and biology.
2. AngelMD previously invested in Artoss in the first quarter of 2016.
3. Artoss' NanoBone technology features hydroxyapatite's nanocrystals suspend in a silica gel matrix.
4. The technology mirrors human bone's hydroxyapatite, and is 100,000 times smaller than other grafting treatments' bioceramic particles.
5. Artoss has found success with its technology in Europe for 10-plus years. The company earned FDA approval as well as purchase approval by the United States Department of Defense.
6. The company launched its NanoBone QD Bone Graft product recently, which is designed to rapidly deliver NanoBone SBX Putty.